Raffles Associates LP Acquires Shares of 403,691 Viemed Healthcare, Inc. $VMD

Raffles Associates LP bought a new stake in Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 403,691 shares of the company's stock, valued at approximately $4,602,000. Viemed Healthcare comprises 3.8% of Raffles Associates LP's investment portfolio, making the stock its 9th biggest position. Raffles Associates LP owned 1.06% of Viemed Healthcare at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of VMD. Kemnay Advisory Services Inc. purchased a new stake in shares of Viemed Healthcare during the fourth quarter worth approximately $46,000. Quarry LP acquired a new stake in shares of Viemed Healthcare during the third quarter worth $48,000. Globeflex Capital L P purchased a new position in Viemed Healthcare in the 2nd quarter valued at $86,000. AQR Capital Management LLC purchased a new position in Viemed Healthcare in the 1st quarter valued at $90,000. Finally, Legal & General Group Plc acquired a new position in Viemed Healthcare in the 2nd quarter valued at $97,000. Institutional investors and hedge funds own 74.24% of the company's stock.

Insiders Place Their Bets

In other news, insider William Frazier sold 10,000 shares of the company's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $11.72, for a total transaction of $117,200.00. Following the transaction, the insider directly owned 73,214 shares of the company's stock, valued at $858,068.08. This represents a 12.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Timothy Smokoff sold 20,000 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $11.50, for a total transaction of $230,000.00. Following the completion of the transaction, the director owned 75,518 shares of the company's stock, valued at $868,457. This represents a 20.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 20.60% of the company's stock.

Viemed Healthcare Stock Down 3.4%

Viemed Healthcare stock opened at $9.01 on Friday. The stock's 50 day moving average price is $10.87 and its 200 day moving average price is $9.90. Viemed Healthcare, Inc. has a 1-year low of $6.05 and a 1-year high of $12.61. The company has a market cap of $343.19 million, a PE ratio of 25.03, a price-to-earnings-growth ratio of 2.30 and a beta of 1.10. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.13 and a quick ratio of 1.02.

Viemed Healthcare (NASDAQ:VMD - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). Viemed Healthcare had a return on equity of 10.16% and a net margin of 4.81%.The business had revenue of $78.10 million during the quarter, compared to analysts' expectations of $78.00 million. On average, sell-side analysts predict that Viemed Healthcare, Inc. will post 0.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VMD has been the subject of a number of analyst reports. Weiss Ratings downgraded shares of Viemed Healthcare from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, August 17th. Wall Street Zen downgraded shares of Viemed Healthcare from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 15th. Barrington Research initiated coverage on shares of Viemed Healthcare in a research note on Monday. They set an "outperform" rating and a $14.00 price target on the stock. Finally, Freedom Capital cut shares of Viemed Healthcare from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $14.00.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc NASDAQ: VMD is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.

Want to see what other hedge funds are holding VMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source